SPRB:NASDAQSpruce Biosciences, Inc. Analysis

Technical outlook: The 20‑day SMA sits just above the 50‑day SMA, while both remain well under the 200‑day SMA, signaling a short‑term neutral stance within a long‑term downtrend. RSI hovers near the mid‑range, and a bearish MACD histogram confirms modest downside pressure. Volume is on the rise, yet the stock trades with a very high 30‑day volatility and a beta exceeding three, indicating amplified market swings. Support lies around the low‑$50s with resistance near the mid‑$70s, and market sentiment is in the “Extreme Greed” zone, suggesting speculative enthusiasm.
Fundamental backdrop: Spruce Biosciences carries a solid cash cushion of roughly $49 M against minimal debt, but it reports negative earnings, EBITDA, and cash flow, reflecting its pre‑revenue biotech stage. Forward earnings estimates turn positive, and the forward P/E of about 13 is well below the industry average of 25, hinting at a valuation discount. Recent material news includes FDA backing for an accelerated approval pathway and a public offering that could fund continued development. Analysts collectively rate the stock as a strong buy with a median target near $170, implying a substantial upside from current levels.